Navigation Links
Contraceptive Spray Shows Positive Clinical Trial Result

The Australian drug delivery company, announced positive results from its Phase 1 clinical studies using two unique contraceptive skin sprays, each containing a progestin and an estrogen .

The first study was a Phase I, pharmacokinetic study, investigating the delivery of a formulation combining Nestorone and the synthetic estrogen, Ethinyl Estradiol. A single dose of the combination formulation was applied to the forearm of healthy volunteers.

The results showed that the dosing of the contraceptive spray provided effective delivery of both contraceptive agents, with blood concentrations of Nestorone and Ethinyl Estradiol in the target range expected to provide effective contraception. The spray was well tolerated, with no serious adverse events recorded.

This is the first time that the Acrux MDTS spray technology has effectively delivered a formulation containing a combination of two drugs, commented Acrux CEO Richard Treagus.

We are particularly pleased that our transdermal spray has been successful with Ethinyl Estradiol, as this is the active pharmaceutical compound in approximately 3 out of every 4 oral contraceptive tablets he added.

Acrux plans to proceed with a multi-dose Phase 1 study in the second half of 2007. The study will be designed to demonstrate that therapeutic blood levels of the combination contraceptive are effectively maintained with once daily dosing.

The second study was a Phase I, pharmacokinetic study, investigating the delivery of a formulation combining Nestorone and the natural estrogen, Estradiol. A single dose of the combination formulation was applied to the forearm of healthy volunteers.

The results showed that the dosing of the contraceptive spray provided effective delivery of Nestorone, with blood concentrations in the target range that is expected to provide effective contraception. The spray was well tolerated, with no serious adv erse events recorded.

Analysis of blood concentrations of Estradiol was inconclusive, due to interaction with background levels of Estradiol in the study population. Acrux has established experience with Estradiol in hormone therapy, with its lead product containing estradiol currently in pre-registration in the USA.

This, along with in-vitro results from a number of formulations containing Estradiol, gives the company confidence that it can deliver this novel combination contraceptive through the skin effectively. Acrux is planning a further Phase 1 study in the second half of 2007 in order to confirm these predictions.

Our strategy over the last 12 months has been to rapidly demonstrate the broad applicability of the Acrux spray technology across a range of contraceptive products, including combination formulations. We have made material progress in this area, which has further strengthened our commercial prospects in the global contraceptive market Richard Treagus said.

Contact:
Dr Richard Treagus, CEO & Managing Director
+61 3 8379 0100
+61 417 520 509
richard.treagus@acrux.com.au


'"/>




Related medicine news :

1. Contraceptives via Internet
2. FDA Approves Contraceptive Ring
3. Contraceptives decreases Libido
4. Contraceptives have dual effects
5. Drugs For Anthrax May Interfere With Oral Contraceptives
6. Contraceptive pill to reduce PMS
7. Smoking and Oral Contraceptives:
8. Contraceptive pills may lead to deformities in babies
9. Low-Dose Oral Contraceptives May Increase Risk For Heart Attack Or Stroke
10. Prevent Multiple Sclerosis From Oral Contraceptives
11. Usage Of Oral Contraceptives Need Not Be Feared By SLE Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: